Trending News Today: Diabetes Increases Risk of Liver Cancer, Cirrhosis in Fatty Liver Disease
Top news of the day from across the health care landscape.
A new study found that individuals with diabetes with nonalcoholic fatty liver disease (NAFLD) may be at an increased risk of cirrhosis and liver cancer, Reuters reported. According to the article, the study examined data on 18 million Europeans to investigate the odds that individuals with NAFLD or nonalcoholic steatohepatitis (NASH) would develop cirrhosis or liver cancer. Among those with NAFLD or NASH, individuals with diabetes were more than twice as likely as those without diabetes to develop liver cirrhosis or cancer, the article reported.
New diabetes cases among US adults has declined, whereas obesity rates are on the rise, The Associated Press reported. According to the article, new federal data released Tuesday is based on a large national survey in which participants were asked whether they had been diagnosed with diabetes and whether the diagnosis was made in the previous year. The report found that the number of new diabetes diagnoses fell to approximately 1.3 million in 2017, which is down from 1.7 million in 2009, the article reported.
A recent study showed that ruxolitinib in combination with buparlisib in myelofibrosis (MF) showed only a modest benefit compared with ruxolitinib alone, The American Journal of Managed Care reported. According to the article, the phase 1B trial investigated the safety and efficacy of ruxolitinib and buparlisib in adults with intermediate/high-risk primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF. Approximately 40% of patients had a spleen volume reduction of 35% or greater with the combination therapy, whereas 41.9% of patients at week 24 and 28% of patients at week 48 who received ruxolitinib alone achieved a spleen volume reduction of 35% or greater, the article reported.